Compare CBRS & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBRS | GH |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0B | 22.9B |
| IPO Year | 2024 | 2018 |
| Metric | CBRS | GH |
|---|---|---|
| Price | $86.94 | $145.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 26 |
| Target Price | ★ $210.18 | $200.76 |
| AVG Volume (30 Days) | ★ 9.9M | 2.1M |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $82.40 | $39.12 |
| Revenue Next Year | $218.73 | $34.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $77.84 | $74.55 |
| 52 Week High | $265.63 | $191.05 |
| Indicator | CBRS | GH |
|---|---|---|
| Relative Strength Index (RSI) | 36.24 | 37.10 |
| Support Level | $77.84 | $138.64 |
| Resistance Level | $221.60 | $177.55 |
| Average True Range (ATR) | 9.85 | 10.03 |
| MACD | 2.51 | -1.96 |
| Stochastic Oscillator | 24.06 | 22.67 |
Cerebras Systems Inc is an AI company. It designs the world's fastest AI infrastructure for training and inference. The company builds the world's largest semiconductor as well as the AI systems to power, cool, and feed the processors data. It develops software to link these systems together into industry-leading supercomputers that are simple to use even for the most complicated AI work, using familiar ML frameworks like PyTorch. Customers use its supercomputers to train industry-leading models. The company uses these supercomputers to run inference at speeds unobtainable from alternative commercial technologies. It delivers these AI capabilities to its customers on-premise and via the cloud. The company generates the majority of its revenue from the USA.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.